2 results about "Oral hypoglycemic" patented technology

The application discloses a Smad5 mutant and application thereof in preventing and treating diabetes.The amino acid sequence of the Smad5 mutant is shown as SEQ NO ID:1.The application further discloses a nucleic acid encoding the Smad5 mutant, a recombinant expression vector containing the nucleic acid and a transformant.The application also includes the application of the nucleic acid, the recombinant expression vector containing the nucleic acid and the transformant in preparing a medicine for preventing and / or treating diabetes.The Smad5 mutant can improve the symptoms of type 1 diabetes and type 2 diabetes in vivo, and has no toxic side effects compared with conventional oral hypoglycemic drugs, and has no damage to the liver and kidney of patients.In addition, an agent for regulating acid-base balance is disclosed, which comprises baking soda alkaline drinking water; the agent can reduce blood sugar and relieve the symptoms of diabetes, and is more economical and convenient to operate for patients.

The application discloses a dual-unit fluorescent sensor array for detecting oral anti-diabetic drugs and application thereof, and relates to a supramolecular fluorescent sensor array which comprises a PAL@Q[8] sensing unit and a bpep-Am@Q[8] sensing unit, wherein the PAL@Q[8] sensing unit is composed of palmatine and Q[8], and the bpep-Am@Q[8] sensing unit is composed of a derivative of 1,4-bis[2-(4-pyridyl)vinyl]benzene and Q[8]. The dual-unit fluorescent sensor array can be used for qualitative detection and quantitative detection of metformin, phenformin, buformin hydrochloride, rosiglitazone and sitagliptin in serum or urine, and the method provides a simple and reliable analysis tool for rapid screening of oral hypoglycemic drugs, clinical blood drug concentration monitoring and identification of hypoglycemia causes, so as to realize on-site rapid visual analysis of oral hypoglycemic drugs.